All Toxicology articles – Page 2
-
ArticleBuilding better drugs: how 3D models are shaping pre-clinical development
Three-dimensional (3D) models are reshaping pre-clinical drug development by providing more accurate insights into drug safety and efficacy. Explore how these advanced in vitro systems help improve predictions and reduce the risk of failure in early-stage drug discovery.
-
NewsCN Bio advances hepatotoxicity testing to reduce drug failures
CN Bio has developed an advanced hepatotoxicity testing solution to improve preclinical drug safety, providing more human-relevant insights and reducing the risk of drug failures due to liver damage.
-
ArticleNew research improves the safety and effectiveness of ADC cancer treatments
Learn how the University at Buffalo is pioneering safer, more effective ADC therapies.
-
ArticleToxicology transformed: Why accuracy now leads the way
Regulatory changes are reshaping toxicology, with precision now at the forefront. We explore how accurate target analysis is transforming drug development, particularly for biotherapeutics.
-
NewsNew network model efficiently identifies cancer driver genes
The model enables researchers to expand the number of tumours that they can study, increasing their ability to detect novel interactions.
-
ArticleRapid delivery of toxicological material
With increasingly rapid timelines for achieving IND-ready processes, a bottleneck has emerged in the provision of toxicology data to support INDs for new therapeutics and hence delivery of FIH studies, explains Alejandro Fernandez Martell and James Berrie from Lonza.
-
ArticleAdvanced techniques in toxicity testing
Tune in to this episode where we explore how innovative assays and human-relevant cell models are transforming toxicity screening in drug development.
-
ArticleUnleashing the potential of lab-grown recombinant polyclonal antibodies
In this Q&A, Sheila Keating, Vice President of Immunology at GigaGen, a Grifols company, explains how its developments in recombinant polyclonal antibody therapies are helping to build a pipeline of highly effective treatments for a wide range of diseases, including the hepatitis B virus.
-
ArticleSRP-001: redefining pain treatment with a safer, non-opioid analgesic
This Q&A with Dr Hernan A Bazan, CEO and Co-founder of South Rampart Pharma, Inc, discusses the potential merits of novel non-opioid analgesic SPR-001, which is Phase II-ready for acute and neuropathic pain and migraines. Its benefits mean it is poised to disrupt the $87 billion pain management market and ...
-
ArticleHow nucleolar stress accelerates aging in mice
Dr Fernández-Capetillo shares his insights from a recent study conducted at the CNIO, elucidating how the expression of (PR)arginine-rich peptides affects ribosomal protein translation and accumulation, and how accelerated aging can be alleviated.
-
NewsInsights into the toxicological effects of nanoparticles
Researchers have developed a system that enabled quantitative assessment of cytotoxicity of SiNPs in human hepatoma cells.
-
WebinarBridging the gap: using organ-on-a-chip as an experimental tool to develop (cost) effective therapeutics
The webinar will explore primary concerns in drug discovery development and why drugs fail.
-
WhitepaperCase study: Mitochondrial toxicity in drug discovery and development
The Agilent Seahorse XF assay platform has opened new avenues for examining mitochondrial health in a timely and effective manner.
-
WebinarInnovations in organoid modelling for disease modelling and cell therapy
Watch our virtual panel, where you'll uncover the game-changing advantages of organoids over traditional 2D cultures. Our experts will explore the immense potential of organoids in oncology and immuno-oncology research.
-
WebinarNormalization of organ-on-a-chip samples for mass spectrometry based proteomics and metabolomics via dansylation-based assay
A discussion of the recently published paper, “Normalization of Organ-on-a-Chip Samples for Mass Spectrometry Based Proteomics and Metabolomics via Dansylation-based Assay,” and how the field can produce more replicable experiments.
-
VideoWebinar: The Role of Neuronal Metabolism in Early Drug Discovery
Learning about the mitochondrial role in a neurodegenerative disorder.
-
VideoWebinar: Accurate detection of mitochondrial toxicity
Using Agilent Seahorse XF technology with the XF Mito Tox Assay allows for streamlined, reliable identification of mitochondrial toxicants.
-
WhitepaperWhitepaper: Cell cycle and DNA damage and repair
Explore pathways of cell cycle control, revealing mechanisms of cell cycle arrest, DNA damage and senescence using this ebook.
-
WhitepaperWhitepaper: Mitochondrial toxicity assessment
This whitepaper establishes a customised XF assay solution for the detection of mitochondrial toxicity using standardised parameters.
-
WhitepaperApplication note: Agilent XF real time ATP rate assay
Discover how the Agilent Seahorse XF Real Time ATP rate assay provides a simple robust workflow that can identify metabolic targets for drug discovery
- Previous Page
- Page1
- Page2
- Page3
- Next Page